BRPI0918008A2 - vetor de expressão e método do mesmo - Google Patents

vetor de expressão e método do mesmo

Info

Publication number
BRPI0918008A2
BRPI0918008A2 BRPI0918008A BRPI0918008A BRPI0918008A2 BR PI0918008 A2 BRPI0918008 A2 BR PI0918008A2 BR PI0918008 A BRPI0918008 A BR PI0918008A BR PI0918008 A BRPI0918008 A BR PI0918008A BR PI0918008 A2 BRPI0918008 A2 BR PI0918008A2
Authority
BR
Brazil
Prior art keywords
expression vector
vector
expression
Prior art date
Application number
BRPI0918008A
Other languages
English (en)
Portuguese (pt)
Inventor
Vyas Ashutosh
Chellappa Gopalakrishnan
Maitya Sunit
Morawala Patell Villoo
Original Assignee
Avesthagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avesthagen Ltd filed Critical Avesthagen Ltd
Publication of BRPI0918008A2 publication Critical patent/BRPI0918008A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BRPI0918008A 2008-08-12 2009-08-12 vetor de expressão e método do mesmo BRPI0918008A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1941CH2008 2008-08-12
PCT/IB2009/006517 WO2010018444A2 (fr) 2008-08-12 2009-08-12 Vecteur d'expression et son procédé

Publications (1)

Publication Number Publication Date
BRPI0918008A2 true BRPI0918008A2 (pt) 2018-07-17

Family

ID=41669395

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918008A BRPI0918008A2 (pt) 2008-08-12 2009-08-12 vetor de expressão e método do mesmo

Country Status (10)

Country Link
EP (1) EP2331693A2 (fr)
JP (1) JP2012506694A (fr)
KR (1) KR20110044769A (fr)
CN (1) CN102177240A (fr)
AU (1) AU2009280913A1 (fr)
BR (1) BRPI0918008A2 (fr)
CA (1) CA2736580A1 (fr)
MX (1) MX2011001644A (fr)
WO (1) WO2010018444A2 (fr)
ZA (1) ZA201101882B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102257141A (zh) * 2008-10-28 2011-11-23 阿维斯塔根有限公司 表达载体和其加工方法
WO2011015918A2 (fr) * 2009-08-03 2011-02-10 Avesthagen Limited Vecteurs et composés pour l'expression de cetuximab de recombinaison
WO2011015916A2 (fr) * 2009-08-03 2011-02-10 Avesthagen Limited Vecteurs et composés pour expression d’infliximab recombinant
WO2011015924A2 (fr) * 2009-08-03 2011-02-10 Avesthagen Limited Vecteurs et composés pour expression du trastuzumab de recombinaison
WO2011015917A2 (fr) * 2009-08-03 2011-02-10 Avesthagen Limited Vecteurs et composés pour expression de tnk-tpa recombinant (tenecteplase)
GB201213117D0 (en) * 2012-07-24 2012-09-05 Ucl Business Plc Transgene expression
CN103740756B (zh) * 2013-12-25 2015-08-05 中国农业大学 一种可调控删除的非病毒游离载体及其构建方法
WO2019057774A1 (fr) * 2017-09-19 2019-03-28 Deutsches Krebsforschungszentrum Vecteurs d'adn non intégrants pour la modification génétique de cellules
EP3456821B2 (fr) * 2017-09-19 2024-01-24 Deutsches Krebsforschungszentrum Vecteurs d'adn non intégrants destinés à la modification génétique de cellules
WO2019088257A1 (fr) * 2017-11-02 2019-05-09 国立大学法人鳥取大学 Procédé de production à haut rendement d'une protéine à l'aide d'un vecteur de chromosome artificiel de mammifère

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU670125B2 (en) * 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US7541512B2 (en) * 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
CN1938428A (zh) * 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统

Also Published As

Publication number Publication date
WO2010018444A3 (fr) 2010-05-14
KR20110044769A (ko) 2011-04-29
ZA201101882B (en) 2012-07-25
MX2011001644A (es) 2011-10-06
WO2010018444A2 (fr) 2010-02-18
JP2012506694A (ja) 2012-03-22
CA2736580A1 (fr) 2010-02-18
AU2009280913A1 (en) 2010-02-18
CN102177240A (zh) 2011-09-07
EP2331693A2 (fr) 2011-06-15

Similar Documents

Publication Publication Date Title
BRPI0918008A2 (pt) vetor de expressão e método do mesmo
BRPI0912934A2 (pt) aparelho e método
BRPI1006537A2 (pt) método e artigo
BRPI0920160A2 (pt) Método de coenchimento de um produto lácteo e produto lácteo composto coenchido
BRPI0920284A2 (pt) composição e método
BRPI1013317A2 (pt) método de cimentação
BRPI0907890A2 (pt) Implantes lacrimais e métodos relacionados
BRPI0910713A2 (pt) método e aparelhos
BR112013001592A2 (pt) artigo e método
BRPI0913227A2 (pt) método, e objeto
BRPI1014864A2 (pt) "implante de processos espinhosos e métodos associados"
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BR112012004222A2 (pt) composições pesticidas espumantes e metodos de aplicação
BRPI1007262A2 (pt) definição de animações simples e complexas
BR112013010847A2 (pt) artigo e método
DK2313489T3 (da) Fremstillingsmetode
BRPI0915849A2 (pt) disposição de vedação e método de vedação
BR112012015031A2 (pt) aparelho e método
BRPI0908798A2 (pt) revestimento de ventilação e método
BRPI0914484A2 (pt) Vetor de expressão e processos deste
IT1396660B1 (it) Apparato e metodo di saldatura
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BRPI0908183A2 (pt) membro embalado e método de produção do mesmo
BR112013016641A2 (pt) artigo e método
BR112012003596A2 (pt) aparelho e método de pré-codificação

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE IN 01941/CHE/2008, REIVINDICADA NO PCT/IB2009/006517, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 2O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPIPR 77/2013. ESTA PERDA SE DEU PELO FATO DE QUE, MESMO APOS A FORMULACAO DE EXIGENCIA PARA TAL, O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DE ENTRADA NA FASE NACIONAL NAO APRESENTOU A TRADUCAO DA FOLHA DE ROSTO, TAMPOUCO APRESENTOU DECLARACAO SUBSTITUTIVA CONTENDO TODOS OS DADOS IDENTIFICADORES DA CITADA PRIORIDADE. CABE SALIENTAR QUE TAL EXIGENCIA SE JUSTIFICA PELO FATO DOS DOCUMENTOS DE PRIORIDADE NAO FORAM ENVIADOS PARA A OMPI, FATO ABORDADO NA EXIGENCIA FORMULADA. TAL

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]